OncoLink Cancer Treatment and Resources
Link to OncoLink

Impact of Risk Factors and

This article has been archived.
Please use for reference only.

Todd Doyle, MD
OncoLink Assistant Editor
Ultima Vez Modificado: 1 de noviembre del 2001

Presenter: Ang, KK
Affiliation: MD Anderson Cancer Center

Background:
We know from the literature that certain patients are at higher risk for postoperative recurrence based on previously described adverse prognostic features. This prospective study was performed to determine:

  1. The validity of these previously defined risk groups and
  2. Whether the total therapy time was an important factor in determining local-regional control and overall survival.
Theoretically, gains in local control may be achieved by decreasing treatment time and offsetting the rapid repopulation of microscopic, postoperative tumor foci.

Materials and Methods:
Two hundred eighty-eight patients with locally advanced sqamous cell carcinoma of the head and neck were prspectively registered in this trial. They underwent radical surgery and were then defined by risk groups based on the following adverse clinicopathologic features: extracapsular extension (ECE)/neck soft tissue extension (STE), oral cavity primary, microsopically positive margins, nerve invasion, >1 neck nodes, >1 positive nodal groups, node size >3cm, and >6 week interval between surgery and radiation. Patients with none of these factors were defined as low risk and received no further treatment after surgery (n=31). Patients with one adverse factor other than ECE/STE were defined as intermediate risk and received lower dose (57.6 Gy) standard fractionation postoperative RT (n=31). Patients with two or more factors or ECE/STE were defined as high risk and were randomized to higher dose (63 Gy) standard fractionation versus higher dose (63 Gy) altered fractionation with a concomitant boost technique. This shortened the RT treatment time from 7 weeks to 5 weeks. The median followup for the entire group was 59 months.

Results:

  • Local-regional control at 4 years was better for the low risk (90%) and intermediate risk (94%) patients than the high risk patients (68%).
  • Overall survival at 4 years was better for the low and intermediate risk groups (83% and 66%) than for the high risk group (43%).
  • For the high risk patients, interval from surgery to postoperative RT was a significant predictor of local-regional control and overal survival for the 7 week arm, but not for the 5 week arm.
  • Overall treatment time (surgery plus postoperative radiation therapy) had a significant impact on local-regional control and overall survival, favoring the shorter treatment times. - Acute side effrects were significantly more common in the 5 week arm than the 7 week arm (62% versus 36%). There was no difference in late toxicity between the two arms.

Clinical/Scientific Implications:

  • This study validated the use of risk clusters to help guide recommendations regarding postoperative radiation therapy.
  • Overall treatment time appears to be an important factor in treating high risk, postoperative head and neck cancer patients.
  • Shorter treatment times using a concomitant boost technique can be achieved without dramatically increasing late toxicity. Future directions for improving the outcomes of high risk, postoperative patients may include the addition of chemotherapy or shortening the interval from surgery to postoperative radiation therapy.

ASTRO coverage is sponsored, in part, by Varian Medical Systems, Inc.

OncoLink I wish u knew...

Dr. Wein discusses prostate cancer, screening and treatment options. Read more.

Cancer Types
Bone Cancer
Brain Tumors
Breast Cancer
Carcinoid Tumors
Endocrine System Cancers
Gastrointestinal Cancers
Gynecologic Cancers
Head and Neck Cancers
Leukemia
Lung Cancers
Lymphomas
Myelomas
Pediatric Cancers
Penile Cancer
Prostate Cancer
Sarcomas
Skin Cancers
Testicular Cancer
Thyroid Cancer
Urinary Tract Cancers
OncoLink Vet

Cancer Treatment
Biologic Therapy
Bone Marrow Transplants
Chemotherapy

Clinical Trials
Complementary Medicine
Gene Therapy
General Treatment Concerns
Hormone Therapy
PDT Center
Proton Therapy
Radiation Oncology
Surgical Oncology
Targeted Therapies
Vaccine Therapies

Cancer Support
Caregivers
Hospice Care and Bereavement
Nutrition and Cancer
Sexuality & Fertility
Side Effects
Support
Survivorship
Exercise and Cancer

Cancer Resources
Cancer News
OncoLink University
Nurses' Notes
Conferences
Newly Diagnosed Patients
Causes and Prevention
Legal and Financial Information for Patients
LGBT Resources
NCI Resources
Global Resources
Cancer Resource List
Resources for Young Adults

OncoLink Media Library
OncoLink TV
Book, Music and Video Reviews


Ask the Experts
Brown Bag Chat
Tracy's Corner

About OncoLink
About OncoLink
Giving to OncoLink
Contact Information
Usage Policy
Editorial Board
How to Partner with OncoLink
Link to OncoLink
Mission Statement

OncoLink Cancer Resources RSS What's New RSS